AstraZeneca’s (AZN) “Hold” Rating Reaffirmed at Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by research analysts at Shore Capital in a research note issued on Tuesday.

A number of other brokerages have also commented on AZN. UBS Group restated a “neutral” rating and set a GBX 5,600 ($73.17) price objective on shares of AstraZeneca in a report on Monday, July 2nd. Deutsche Bank dropped their price objective on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 5,700 ($74.48) and set a “buy” rating on the stock in a report on Friday, July 20th. BNP Paribas set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, September 11th. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, September 25th. Finally, Barclays set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Friday, July 27th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of GBX 5,705.70 ($74.56).

Shares of LON AZN opened at GBX 5,864 ($76.62) on Tuesday. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).



About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Google Finance Portfolio Workaround

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply